LY-364947
LY-364947은 transforming growth factor beta pathway의 선택적 억제제로서, 관련 세포주에서 TGF-beta 의존적 성장을 억제합니다.
또한 MatriGel invasion assay에서 MDA-MB-231 유방암 세포를 억제하고, 인간 줄기세포에서 연골 형성을 차단하는 것으로 보고되었습니다.
| SIZE | PRICE (부가세별도) | 제품번호 |
|---|---|---|
| 5mg | $95.00 |
3965362-5mg
|
| 10mg | $180.00 |
3965362-10mg
|
- Preparation & Storage
Soluble in organic solvents such as DMF or DMSO. DMSO up to 1mg/ml. ( 3.6724 mM ). - Download TDS
ADDITIONAL INFORMATION
|
Applications:
|
FA
|
|
Synonyms:
|
TbetaR-I Inhibitor, LY364947, LY 364947, Transforming Growth Factor-beta Type I Receptor Kinase Inhibitor
|
|
Formulation:
|
Crystalline solid
|
|
Chemical Name:
|
4-(5-pyridin-2-yl-1H-pyrazol-4-yl)quinoline
|
|
Molecular Formula:
|
C17H12N4 |
|
Molecular Weight:
|
272.3
|
|
CAS Number
|
396129-53-6
|
|
Purity:
|
≥98%
|
|
Storage Conditions:
|
Product should be kept at -20°C.
|
|
References:
|
S Bansal, S., Celia, C., Ferrati, S., Zabre, E., Ferrari, M., Palapattu, G., & Grattoni, A. (2013). Validated RP-HPLC method for the simultaneous analysis of gemcitabine and LY-364947 in liposomal formulations. Current drug targets,14(9), 1061-1069. Nassar, K., Tura, A., Lueke, J., Lueke, M., & Grisanti, S. (2012). The novel use of LY364947 (LY), a TGF-ß Type I receptor inhibitor, in prevention of proliferative vitreoretinopathy (PVR). Investigative Ophthalmology & Visual Science, 53(14), 893-893. Oka, M., Iwata, C., Suzuki, H. I., Kiyono, K., Morishita, Y., Watabe, T., … & Miyazono, K. (2008). Inhibition of endogenous TGF-β signaling enhances lymphangiogenesis. Blood, 111(9), 4571-4579. |
상품평
아직 상품평이 없습니다.